These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins. Naiki H; Nagai Y J Biochem; 2009 Dec; 146(6):751-6. PubMed ID: 19643812 [TBL] [Abstract][Full Text] [Related]
4. [Amyloidosis: a model of misfolded protein disorder]. Grateau G; Verine J; Delpech M; Ries M Med Sci (Paris); 2005; 21(6-7):627-33. PubMed ID: 15985206 [TBL] [Abstract][Full Text] [Related]
5. Extracellular chaperones and proteostasis. Wyatt AR; Yerbury JJ; Ecroyd H; Wilson MR Annu Rev Biochem; 2013; 82():295-322. PubMed ID: 23350744 [TBL] [Abstract][Full Text] [Related]
6. Amino acid sequence determinants and molecular chaperones in amyloid fibril formation. Nerelius C; Fitzen M; Johansson J Biochem Biophys Res Commun; 2010 May; 396(1):2-6. PubMed ID: 20494101 [TBL] [Abstract][Full Text] [Related]
7. How a cell deals with abnormal proteins. Pathogenetic mechanisms in protein aggregation diseases. Aigelsreiter A; Janig E; Stumptner C; Fuchsbichler A; Zatloukal K; Denk H Pathobiology; 2007; 74(3):145-58. PubMed ID: 17643060 [TBL] [Abstract][Full Text] [Related]
8. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis]. Yoshida K; Higuchi K; Ikeda S Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474 [TBL] [Abstract][Full Text] [Related]
9. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins. Meredith SC Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927 [TBL] [Abstract][Full Text] [Related]
10. Protein-misfolding diseases and chaperone-based therapeutic approaches. Chaudhuri TK; Paul S FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923 [TBL] [Abstract][Full Text] [Related]
11. Chapter 6: The chaperone action of Clusterin and its putative role in quality control of extracellular protein folding. Wyatt A; Yerbury J; Poon S; Dabbs R; Wilson M Adv Cancer Res; 2009; 104():89-114. PubMed ID: 19878774 [TBL] [Abstract][Full Text] [Related]
12. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Wilson MR; Yerbury JJ; Poon S Mol Biosyst; 2008 Jan; 4(1):42-52. PubMed ID: 18075673 [TBL] [Abstract][Full Text] [Related]
14. Clearance of extracellular misfolded proteins in systemic amyloidosis: experience with transthyretin. Almeida MR; Saraiva MJ FEBS Lett; 2012 Aug; 586(18):2891-6. PubMed ID: 22819819 [TBL] [Abstract][Full Text] [Related]
15. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. Chiti F; Dobson CM Annu Rev Biochem; 2017 Jun; 86():27-68. PubMed ID: 28498720 [TBL] [Abstract][Full Text] [Related]
16. How our bodies fight amyloidosis: effects of physiological factors on pathogenic aggregation of amyloidogenic proteins. Huang L; Liu X; Cheng B; Huang K Arch Biochem Biophys; 2015 Feb; 568():46-55. PubMed ID: 25615529 [TBL] [Abstract][Full Text] [Related]
17. Implications of protein structure instability: from physiological to pathological secondary structure. Sukhanova A; Poly S; Shemetov A; Bronstein I; Nabiev I Biopolymers; 2012 Aug; 97(8):577-88. PubMed ID: 22605549 [TBL] [Abstract][Full Text] [Related]